483
ICON plcFDA 483 - ICON plc - October 24, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Record Details
An FDA inspection of ICON plc's bioanalytical facility in Assen, Netherlands, revealed a significant deficiency in method validation activities. The firm failed to adequately evaluate the specificity of bioanalytical methods for certain compounds in the presence of all co-administered medications during a study. This indicates a potential issue with the reliability of the analytical data.
Open in Dashboard
ID · 7cb74697-beea-47f5-926a-54f82ffc142d